Oxycodone HCL-Acetaminophen Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D221R0114

NAICS

-

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Hobart, New York, UNITED STATES

SourceSAM
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the ongoing procurement of Oxycodone HCL-Acetaminophen Tablets. This contract, identified by procurement number SPE2D221R0114 and award number SPE2D2-22-D-0150, is structured as a multi-year agreement with several exercised option years, reflecting the agency’s commitment to ensuring a consistent and reliable supply of this critical pharmaceutical product. The primary objective of this procurement is to secure the supply of Oxycodone HCL/Acetaminophen Tablets, a combination medication widely used for pain management, to support the needs of federal entities. The contract encompasses multiple line items (0001 through 0005), indicating a range of product specifications or packaging configurations to meet diverse operational requirements. The place of performance is specified as Hobart, New York, ensuring centralized distribution and fulfillment within the United States. Throughout the contract lifecycle, several key modifications have been incorporated to address evolving regulatory and policy requirements. Notably, the contract has been updated to include language from the Drug Supply Chain Security Act (DSCSA), ensuring compliance with federal standards for pharmaceutical traceability and safety. Additionally, the contract now incorporates FAR 52.204-27, which prohibits the use of Bytedance covered applications, reflecting cybersecurity and supply chain integrity priorities. A mass modification was also executed in response to relevant Executive Orders, further aligning the contract with current federal directives. A significant recent modification (P00008) introduced clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1), effective April 2026. This addition underscores the government’s commitment to diversity, equity, and inclusion in its contracting practices and imposes specific compliance obligations on the contractor. The contract is classified under Product Service Code 6505, which pertains to drugs and biologicals, and is managed by the DLA Troop Support office. The primary point of contact for this procurement is Courtney Hunter-Stangler ([email protected], 215-737-6845), with secondary support provided by Catherine Gilbert ([email protected], 445-737-8868). Contractors interested in this opportunity should note that the contract is active and that all relevant documentation and modifications are accessible via the official SAM.gov listing (Opportunity ID: 4aca076cbdbf474ea4f758f9b7d61f50). This procurement is a federal contract with no explicit set-aside or special socioeconomic considerations indicated in the provided information. The scope and requirements are expected to remain stable over the contract’s duration, with ongoing compliance to federal regulations and policy updates as a constant expectation. Contractors evaluating this opportunity should ensure robust capabilities in pharmaceutical manufacturing, regulatory compliance, and supply chain management to meet the DLA’s stringent standards and evolving contractual requirements.
Documents9